JNJ vs MGNX

JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.

MGNX exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 0/9, indicating severe deterioration across all financial health dimensions. While the company shows explosive revenue growth (113% YoY) and maintains a strong liquidity position (Current Ratio 5.10), it suffers from negative gross margins and a consistent track record of missing earnings estimates. The recent 1-year price surge appears decoupled from fundamental value, as the company remains deeply unprofitable with a catastrophic ROE of -86.94%.